BioCentury | Jun 24, 2019
Tools & Techniques

A new flavor of allosteric modulators: synthetic proteins

Relay co-founder and Brandeis Professor Dorothee Kern is turning to synthetic proteins rather than small molecules to drug targets at allosteric sites, a strategy she thinks will shorten the discovery process and provide added selectivity....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Jan 11, 2019
Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in...
BioCentury | Jan 7, 2019
Company News

Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) has reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting AURKA, AURKB and AURKC could enhance the efficacy of T790M-mutant EGFR inhibitors against EGFR-mutant NSCLC. Screening of 94 compounds against cancer pathway...
BioCentury | Jun 28, 2018
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node...
BioCentury | May 31, 2018
Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
BioCentury | May 18, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing on May 14 to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal came just four...
BioCentury | May 14, 2018
Company News

Lilly continues to build cancer pipeline with AurKa acquisition

Eli Lilly and Co. (NYSE:LLY) signed another bolt-on deal to build its cancer pipeline, agreeing Monday to buy AurKa Pharma Inc. (Montreal, Quebec) for up to $575 million. The deal comes just four days after...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Inflammation

...vehicle. Next steps could include testing the two compounds in additional models of SIRS. TARGET/MARKER/PATHWAY: Aurora kinases...
...13, 2018 doi:10.1021/acs.jmedchem.7b01449 CONTACT: Koen Augustyns, University of Antwerp, Antwerp, Belgium email: koen.augustyns@uantwerpen.be Claire Quang University of Antwerp Aurora kinases Tumor...
Items per page:
1 - 10 of 208